Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines.
Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Schmitz-Dräger BJ, et al. Among authors: sanchez carbayo m. Urol Oncol. 2016 Oct;34(10):437-51. doi: 10.1016/j.urolonc.2016.05.030. Epub 2016 Sep 15. Urol Oncol. 2016. PMID: 27641313 Review.
Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer.
Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat A. Schmitz-Dräger BJ, et al. Urol Oncol. 2014 Oct;32(7):1061-8. doi: 10.1016/j.urolonc.2013.10.010. Epub 2014 Jan 9. Urol Oncol. 2014. PMID: 24411790 Review.
Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer.
Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Kamat AM, et al. Urol Oncol. 2014 Oct;32(7):1069-77. doi: 10.1016/j.urolonc.2014.06.017. Epub 2014 Oct 11. Urol Oncol. 2014. PMID: 25306288 Review.
Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network.
Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM. Zuiverloon TCM, et al. Among authors: sanchez carbayo m. Urol Oncol. 2018 Sep;36(9):423-431. doi: 10.1016/j.urolonc.2018.01.014. Epub 2018 Mar 2. Urol Oncol. 2018. PMID: 29496372 Review.
External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.
Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ. Chen LM, et al. Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24920641 Free PMC article.
Profilin 1 is a potential biomarker for bladder cancer aggressiveness.
Zoidakis J, Makridakis M, Zerefos PG, Bitsika V, Esteban S, Frantzi M, Stravodimos K, Anagnou NP, Roubelakis MG, Sanchez-Carbayo M, Vlahou A. Zoidakis J, et al. Mol Cell Proteomics. 2012 Apr;11(4):M111.009449. doi: 10.1074/mcp.M111.009449. Epub 2011 Dec 8. Mol Cell Proteomics. 2012. PMID: 22159600 Free PMC article.
Recent advances in bladder cancer diagnostics.
Sanchez-Carbayo M. Sanchez-Carbayo M. Clin Biochem. 2004 Jul;37(7):562-71. doi: 10.1016/j.clinbiochem.2004.05.014. Clin Biochem. 2004. PMID: 15234237 Review.
103 results